Status:
UNKNOWN
Iodine Subtraction Mapping in the Diagnosis of Chronic Pulmonary Thromboembolic Disease
Lead Sponsor:
University of Sheffield
Collaborating Sponsors:
Sheffield Teaching Hospitals NHS Foundation Trust
Conditions:
Chronic Thromboembolic Pulmonary Hypertension
Eligibility:
All Genders
18-90 years
Brief Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe but treatable disease that is commonly underdiagnosed. Computed tomography lung subtraction iodine mapping (CT-LSIM) in addition to st...
Detailed Description
Chronic thromboembolic pulmonary hypertension (CTEPH) is a treatable, life-threatening disease that occurs in up to 4% of patients following acute pulmonary embolism (PE)(1). The disease is characteri...
Eligibility Criteria
Inclusion
- Patients suspected to have CTED and require a SPECT and CTPA
Exclusion
- Less than 18 years old
- Unable to provide informed consent
- Significant renal dysfunction (GFR \<30ml/min)
- History of hypersensitivity to contrast material
- Pregnancy
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03806907
Start Date
April 1 2019
End Date
August 30 2020
Last Update
February 12 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.